ClinicalTrials.gg
Active, not recruitingNCT05593094Updated Aug 21, 2026

A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors

A Phase 1/2 interventional study of ZN-A-1041 and ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1b in Advanced Solid Tumors and HER2-positive Breast Cancer, sponsored by Hoffmann-La Roche. Active, not recruiting at 36 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-21.

Sponsored by Hoffmann-La Roche · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 1 month after the study started (first participant enrolled Sep 2020, registered Oct 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
210
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 67 studies in Brain Neoplasms with a site in Spain — 12 open to participants now, 26 under way, 4 of them phase 3. Brain Neoplasms · Spain.

Planned enrollment
25th of 62
210 · median 73
Started
2020
with 4 others
Phase 1/2
12 of 67
2 open now
Primary completion
2027-08
later than 16 of 25 live
Registered
54th of 67
by date
Lead sponsor
3 of 67
Hoffmann-La Roche

Among the 67 studies in Brain Neoplasms with a site in Spain, this one is the 25th largest by planned enrollment of the 62 interventional ones that give a count, is one of 5 that started in 2020, is one of 12 in phase 1/2, reaches primary completion later than 16 of the 25 other live ones, and was the 54th registered.

Brain Neoplasms

2,441 studies on the registry are indexed under Brain Neoplasms; 541 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

12 of the 67 studies in Brain Neoplasms with a site in Spain are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 425 Brain Neoplasms studies recruiting now, 286 (67%) set no upper age limit and 82 (19%) stop at 75 or younger; 80 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Brain Neoplasms with a site in Spain, or all of them as a file.
02

Study summary

This will be a Phase 1, multicenter, open-label trial to evaluate the safety, tolerability, PK and efficacy of ZN-A-1041 as a monotherapy or in combination in participants with HER2-positive advanced solid tumors with or without brain metastases.

The study will consist of three phases: Phase 1a (dose escalation with ZN-A-1041 monotherapy), Phase 1b (dose escalation with ZN-A-1041 combination therapy) and Phase 1c (dose expansion with ZN-A-1041 combination therapy).

Read the detailed description

This study is composed of three parts designed to evaluate the safety and efficacy of ZN-A-1041 in participants with HER2-positive advanced solid tumors.

Phase 1a (Monotherapy Dose Escalation): In this first phase, participants will receive ZN-A-1041 alone. The study will begin with a low dose of ZN-A-1041, which will be gradually increased in new groups of participants to find the highest dose that can be given safely. This will establish the recommended dose for further study.

Phase 1b (Combination Dose Escalation): In the second phase, the study will evaluate the safety of giving ZN-A-1041 together with established standard-of-care therapies for HER2-positive breast cancer. Participants will be enrolled into one of three combination arms to receive ZN-A-1041 with either T-DM1, T-DXd, or a pertuzumab/trastuzumab-based regimen. This phase will identify the recommended dose for these combination therapies.

Phase 1c (Combination Dose Expansion): In the final phase, additional participants will be enrolled to receive ZN-A-1041 at the recommended combination doses identified in Phase 1b. This will allow for a more thorough evaluation of the safety and preliminary efficacy of these treatment regimens.

Throughout the study, participants will undergo screening, treatment, and follow-up periods to collect comprehensive data on the safety, tolerability, pharmacokinetics, and anti-tumor activity of ZN-A-1041, both as a single agent and in combination.

03

Conditions studied

  • Advanced Solid Tumors
  • HER2-positive Breast Cancer

Browse trials for

Keywords

  • Phase 1
  • Advanced Solid Tumors
  • HER2 postive
  • Brain metastases
  • Herceptin
  • Perjeta
  • PHESGO
  • First Line
  • 1st Line
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ECOG) performance status of 0 or 1
  • of at least 6 months, as determined by the investigator
  • or cytologically confirmed with unresectable or -positive advanced solid tumors
  • Must be after prior treatment for metastatic disease that included a taxane and trastuzumab or must have received induction therapy for advanced disease a pertuzumab plus trastuzumab-based regimen or a T-DXd-based regimen
  • Participants with new, untreated, progressive, or stable are eligible

Exclusion criteria

Exclusion Criteria:

  • Participation in any other clinical study involving an drug or device within 4 weeks prior to the first dose of study treatment
  • Any intracranial lesion () that requires immediate local therapy, such as surgery or radiation, or systemic at the time of enrollment
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
210 participants (estimated)

Study arms

  • Experimental
    1a: ZN-A-1041

    Phase 1a: Participants will receive escalating doses of ZN-A-1041 orally twice a day (BID) at pre-defined dosing regimens to determine the maximum tolerated dose (MTD).

    Drug: ZN-A-1041

  • Experimental
    1b: ZN-A-1041 + T-DM1 3.6 mg/kg iv.

    Phase 1b Arm1: 1. If the maximum tolerated dose (MTD) of ZN-A-1041 is identified in Phase 1a study: The 2 tentative dose levels of ZN-A-1041 are MTD-1 (Level 1) and MTD (Level 2). 2. If the MTD is still not reached at the maximum dose level in Phase 1a study, the maximum dose level of ZN-A-1041 in Phase 1a will be used in Phase 1b study.

    Drug: ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1b

  • Experimental
    1b: ZN-A-1041 + T-Dxd 5.4 mg/kg iv.

    Phase 1b Arm2: 1. If the MTD of ZN-A-1041 is identified in Phase 1a study: The 2 tentative dose levels of ZN-A-1041 are MTD-1 (Level 1) and MTD (Level 2). 2. If the MTD is still not reached at the maximum dose level in Phase 1a study, the maximum dose level of ZN-A-1041 in Phase 1a will be used in Phase 1b study.

    Drug: ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1b

  • Experimental
    1b: ZN-A-1041 + PHESGO / Herceptin plus Perjeta

    Phase 1b Arm3: 1. If the MTD of ZN-A-1041 is identified in Phase 1a study: The 2 tentative dose levels of ZN-A-1041 are MTD-1 (Level 1) and MTD (Level 2). 2. If the MTD is still not reached at the maximum dose level in Phase 1a study, the maximum dose level of ZN-A-1041 in Phase 1a will be used in Phase 1b study.

    Drug: ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1b

  • Experimental
    1c: ZN-A-1041 + T-DM1 3.6 mg/kg iv.

    Phase 1c Arm1: The recommended dose combination for Phase 1c will be determined by the Investigator and the Sponsor based on the data from Phase 1b.

    Drug: ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1c

  • Experimental
    1c: ZN-A-1041 + T-Dxd 5.4 mg/kg iv.

    Phase 1c Arm2: The recommended dose combination for Phase 1c will be determined by the Investigator and the Sponsor based on the data from Phase 1b.

    Drug: ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1c

  • Experimental
    1c: ZN-A-1041 + Herceptin plus Perjeta/PHESGO

    Phase 1c Arm3: The recommended dose combination for Phase 1c will be determined by the Investigator and the Sponsor based on the data from Phase 1b.

    Drug: ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1c

Interventions

  • ZN-A-1041: escalating doses orally BID at pre-defined dosing regimens to determine the MTD

    Also known as: ZN-A-1041 Enteric Capsules

  • DrugZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1b

    Drug page: Bizrolertinib

    ZN-A-1041: BID via oral administration T-DM1: 3.6 mg/kg given as an intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)

    Also known as: ZN-A-1041 Enteric Capsules

  • DrugZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1b

    Drug page: Bizrolertinib

    ZN-A-1041: BID via oral administration T-DXd: 5.4 mg/kg given as an intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)

    Also known as: ZN-A-1041 Enteric Capsules

  • DrugZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1b

    Drug page: Bizrolertinib

    ZN-A-1041: BID via oral administration PHESGO dose is 600 mg pertuzumab/600 mg trastuzumab/2000 unites hyaluronidase every 3 weeks for subcutaneous administrations (21-day cycle) Perjeta is 420 mg administered as an intravenous infusion Herceptin is 6 mg/kg administered as an intravenous infusion

    Also known as: ZN-A-1041 Enteric Capsules

  • DrugZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1c

    Drug page: Bizrolertinib

    ZN-A-1041: BID via oral administration T-DM1: intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)

    Also known as: ZN-A-1041 Enteric Capsules

  • DrugZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1c

    Drug page: Bizrolertinib

    ZN-A-1041: BID via oral administration T-DXd: intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)

    Also known as: ZN-A-1041 Enteric Capsules

  • DrugZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1c

    Drug page: Bizrolertinib

    ZN-A-1041: BID via oral administration PHESGO: every 3 weeks for subcutaneous administrations (21-day cycle) Perjeta: intravenous infusion Herceptin: intravenous infusion

    Also known as: ZN-A-1041 Enteric Capsules

This study also gives Trastuzumab, Pertuzumab, Ado-Trastuzumab Emtansine. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. The Incidence of Treatment-emergent Adverse Events of ZN-A-1041 as a Monotherapy in Phase 1a

    Dose at which no more than one out of six participant at the same dose level experiences a probable drug-related DLT.

    Time frame: 23 days

  2. The Incidence of Treatment-emergent Adverse Events of ZN-A-1041 in Combination with T-DM1 or with T-DXd, or in Combination with PHESGO or Herceptin plus Perjeta

    Dose at which no more than one out of six participant at the same dose level experiences a probable drug-related DLT.

    Time frame: 21 days

  3. RP2D

    To evaluate the safety of ZN-A-1041 in combination with T-DM1 or with T-DXd, or in combination with PHESGO or Herceptin plus Perjeta in participants on the RP2D.

    Time frame: Through study completion, an average of 1 year

Secondary outcomes

  1. Plasma, Urine and Potentially Cerebrospinal Fluid (CSF) Level of ZN-A-1041 and its Main Metabolites

    To assess the PK of ZN-A-1041 and its major metabolites.

    Time frame: From baseline to cycle 9 (each cycel is 21 days)

  2. Serum Level of Combination Drugs in Phase 1c

    To assess the serum concentration of combination drugs.

    Time frame: Through study completion, an average of 2 year

  3. Anti-drug Antibodies (ADAs) Evaluation in Phase 1c

    To assess the incidence of ADAs.

    Time frame: Through study completion, an average of 2 year

  4. Overall Response Rate (ORR)

    The preliminary efficacy of ZN-A-1041 as a monotherapy or combination in Phase 1a, Phase 1b and 1c.

    Time frame: Through study completion, an average of 2 year

  5. Progression Free Survival (PFS)

    The preliminary efficacy of ZN-A-1041 as a monotherapy or combination in Phase 1a, Phase 1b and 1c.

    Time frame: Through study completion, an average of 2 year

07

Study locations

36 sites
08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2020 (actual). Primary completion is estimated for Aug 2027, 83 months after the start.

Of 72 phase 1/2 interventional studies under Brain Neoplasms, half reached primary completion within 82 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 105. This study's planned 83 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2022
First posted
Oct 25, 2022
StartActual
Sep 3, 2020
Primary completionEst.
Aug 31, 2027
CompletionEst.
Aug 31, 2027
Last update
Aug 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05593094
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Oct 25, 2022
Start date
Sep 3, 2020
Primary completion
Aug 31, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Aug 21, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bizrolertinib

Start the discussion